Sai Life

Why is Sai Life Sciences Ltd falling/rising?

As of 19-Aug, Sai Life Sciences Ltd's stock price is at 1,422.60, down 1.12%, due to underperformance relative to its sector and decreased investor participation. Despite these short-term challenges, the company has demonstrated strong long-term growth with an annual operating profit growth rate of 81.11%.

As of 19-Aug, Sai Life Sciences Ltd's stock price is falling, currently at 1,422.60, which reflects a decrease of 16.05 or 1.12%. This decline can be attributed to several factors. Firstly, the stock has underperformed its sector today by 1.13%, indicating weaker performance relative to its peers. Additionally, there has been a noticeable drop in investor participation, with delivery volume on 18 August falling by 8.89% compared to the 5-day average. This decrease in trading activity suggests reduced interest from investors, which can contribute to downward pressure on the stock price.<BR><BR>Despite these short-term challenges, it is important to note that Sai Life Sciences Ltd has shown strong long-term growth, with an operating profit growth rate of 81.11% annually and a significant return of 56.21% over the past year, outperforming the broader market. However, the current performance metrics indicate that the stock is facing some headwinds, leading to its recent price decline.

Which are the latest news on Sai Life?

What does Sai Life do?

Sai Life Sciences Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 554 Cr and a net profit of 73 Cr for June 2026, with a market cap of INR 31,256 Cr. Key metrics include a P/E ratio of 84.00 and a debt-equity ratio of 0.05.

Overview: <BR>Sai Life Sciences Ltd is a small-cap company operating in the Pharmaceuticals & Biotechnology industry.<BR><BR>History: <BR>Sai Life Sciences Limited was originally incorporated as Sai Dru Syn Laboratories Limited in 1999. The company changed its name to Sai Life Sciences Limited in 2003. The most recent quarterly results report net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 554 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 73 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 31,256 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 84.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.05 <BR>Return on Equity: 14.29% <BR>Price to Book: 12.53 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Sai Life?

Sai Life's peers include Gland Pharma, Ajanta Pharma, Ipca Labs, Glaxosmi Pharma, Emcure Pharma, Wockhardt, Neuland Labs, Piramal Pharma, and Acutaas Chemical. In terms of management risk, growth, and capital structure, Sai Life shows average management risk and excellent growth, with a 1-year return of 60.82%.

Peers: The peers of Sai Life are Gland Pharma, Ajanta Pharma, Ipca Labs, Glaxosmi. Pharma, Emcure Pharma, Wockhardt, Neuland Labs., Piramal Pharma, and Acutaas Chemical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Ajanta Pharma and Glaxosmi. Pharma, while Good management risk is found at Gland Pharma, Ipca Labs, Emcure Pharma, Neuland Labs., and Acutaas Chemical. Average management risk is present at Sai Life, Wockhardt, and Piramal Pharma. Growth is Excellent at Sai Life, Emcure Pharma, Neuland Labs., and Acutaas Chemical, while Below Average growth is noted at Gland Pharma, Ajanta Pharma, Ipca Labs, Glaxosmi. Pharma, Wockhardt, and Piramal Pharma. Capital Structure is Excellent for Gland Pharma, Ajanta Pharma, Ipca Labs, Glaxosmi. Pharma, Sai Life, Emcure Pharma, and Neuland Labs., while Good is observed at Emcure Pharma, and Below Average at Wockhardt and Piramal Pharma.<BR><BR>Return Snapshot: Neuland Labs. has the highest 1-year return at 78.35%, while Glaxosmi. Pharma has the lowest at -3.93%. Sai Life's 1-year return of 60.82% is significantly higher than Glaxosmi. Pharma's. Additionally, Acutaas Chemical is the only peer with a negative six-month return.

How big is Sai Life?

As of 14th August, Sai Life Sciences Ltd has a market capitalization of 30,627.79 Cr, with recent net sales of 2,250.36 Cr and a net profit of 361.75 Cr.

As of 14th August, Sai Life Sciences Ltd has a market capitalization of 30,627.79 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Sai Life reported Net Sales of 2,250.36 Cr and a Net Profit of 361.75 Cr.<BR><BR>For the latest annual period ending in March 2025, the company had Shareholder's Funds amounting to 2,128.35 Cr and Total Assets of 3,145.78 Cr.

Should I buy, sell or hold Sai Life Sciences Ltd?

Are Sai Life Sciences Ltd latest results good or bad?

Sai Life Sciences Ltd's latest results show record net sales and profit growth, but declining operating margins raise concerns about profitability and competitive positioning. Overall, while revenue and profit increases are positive, margin compression suggests mixed results for investors.

Sai Life Sciences Ltd's latest results present a mixed picture. On one hand, the company achieved a record net sales of ₹602.14 crores in Q4 FY26, reflecting an 8.21% increase quarter-on-quarter and a modest 3.91% year-on-year growth. Additionally, net profit rose to ₹104.24 crores, marking an 18.09% increase year-on-year and a 3.85% rise sequentially.<BR><BR>However, there are concerns regarding profitability. The operating margin, excluding other income, contracted significantly to 29.32% from 33.76% in the previous quarter, indicating pressure on margins. This decline raises questions about the company's pricing power and cost management in a competitive environment. Furthermore, the return on equity at 12.62% is below that of some peers, which may be a concern for investors.<BR><BR>Overall, while the revenue and profit growth are positive indicators, the margin compression and valuation concerns suggest that the results are not entirely favorable. Investors should closely monitor the company's ability to sustain growth and manage margins moving forward.

When is the next results date for Sai Life Sciences Ltd?

The next results date for Sai Life Sciences Ltd is 05 February 2026.

The next results date for Sai Life Sciences Ltd is scheduled for 05 February 2026.

How has been the historical performance of Sai Life?

Sai Life experienced significant financial growth from March 2024 to March 2025, with net sales rising to 1,694.57 Cr and profit after tax increasing to 170.13 Cr. The company improved its operating profit margin to 23.94% and reduced total debt from 710.16 Cr to 128.64 Cr.

Answer:<BR>The historical performance of Sai Life shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Sai Life's consolidated net sales increased from 1,465.18 Cr in March 2024 to 1,694.57 Cr in March 2025, reflecting a strong upward trend in total operating income as well. The company's total expenditure rose to 1,288.91 Cr from 1,179.69 Cr, with notable increases in raw material costs and employee costs. Operating profit (PBDIT) improved significantly, reaching 442.44 Cr, up from 314.58 Cr, while profit before tax also saw a substantial rise to 227.70 Cr from 109.23 Cr. Consequently, profit after tax surged to 170.13 Cr compared to 82.81 Cr the previous year. The operating profit margin increased to 23.94% from 19.48%, and the PAT margin improved to 10.04% from 5.65%. On the balance sheet, total assets grew to 3,145.78 Cr from 2,262.00 Cr, driven by increases in shareholder's funds and cash reserves, which rose to 463.88 Cr from 158.80 Cr. The company also reduced its total debt significantly from 710.16 Cr to 128.64 Cr. Overall, Sai Life demonstrated robust financial growth and improved profitability in the fiscal year ending March 2025.

Is Sai Life technically bullish or bearish?

As of June 23, 2025, the market trend is neutral with no strong signals, indicating a consolidation phase despite mildly bullish Bollinger Bands.

As of 23 June 2025, the technical trend has changed from mildly bullish to sideways. The current stance is neutral, with no strong bullish or bearish signals present. The MACD and KST indicators show no clear trend on both weekly and monthly time frames. The RSI is also indicating no signal on the weekly and monthly charts. While the Bollinger Bands are mildly bullish on the weekly, the overall lack of definitive trends in the moving averages, Dow Theory, and OBV suggests a consolidation phase. The recent price action, with a decline from the previous close, further supports this neutral outlook.

Is Sai Life overvalued or undervalued?

As of February 7, 2025, Sai Life is considered overvalued with a "very expensive" rating due to high valuation metrics like a PE ratio of 88.33 and an EV to EBITDA of 38.80, significantly exceeding its peers, despite recent stock performance outpacing the Sensex.

As of 7 February 2025, Sai Life has moved from a grade of "does not qualify" to "very expensive." The company is currently overvalued based on its high valuation metrics, including a PE ratio of 88.33, an EV to EBIT of 57.30, and an EV to EBITDA of 38.80. These figures significantly exceed those of its peers, such as Sun Pharmaceutical Industries Ltd., which has a PE ratio of 35.25 and an EV to EBITDA of 24.91, and Cipla Ltd., which boasts a much lower PE ratio of 22.99 and an EV to EBITDA of 15.93.<BR><BR>In comparison to its industry, Sai Life's valuation appears excessive, particularly when considering its PEG ratio of 0.00, indicating no growth expectations priced into the stock. The company's recent stock performance has outpaced the Sensex, with a 1-week return of 4.16% compared to the Sensex's 1.35%, suggesting some investor optimism despite the high valuation. Overall, given the significant premium over its peers and the valuation grade, Sai Life is deemed overvalued.

Who are the top shareholders of the Sai Life?

The top shareholders of Sai Life include Tpg Asia Vii Sf Pte Ltd with 24.73%, promoter Mytreyi Kanumuri at 10.64%, mutual funds holding 11.54%, and foreign institutional investors at 12.36%, while individual investors own 7.69%. A small portion of promoter holdings is pledged at 2.6741%.

The top shareholders of Sai Life include a mix of institutional and individual investors. The largest public shareholder is Tpg Asia Vii Sf Pte Ltd, holding 24.73%. Among the promoters, Mytreyi Kanumuri, a partner at Marigold Partners, has the highest stake at 10.64%. Additionally, mutual funds hold 11.54% of the shares through 21 schemes, while foreign institutional investors (FIIs) account for 12.36% with 73 FIIs involved. Individual investors collectively hold 7.69% of the company. The majority of the shareholding is held by non-institutional investors, with a small portion of promoter holdings being pledged at 2.6741%.

Has Sai Life declared dividend?

No Dividend History Available